Four highly experienced and successful domestic Clinical Research Sites (CRS) will form the HIV Centers for Underrepresented Populations in REsearch (HIV CURE) CTU. The CTU will be located at the University of California San Diego (UCSD) with Stephen A. Spector serving as the PI. The 4 CRSs are located at Baylor College of Medicine in Houston (William T. Shearer, Leader), Lurie Children's Hospital in Chicago (Northwestern - Ram Yogev, Leader), St. Jude Children's Research Hospital/University of Tennessee in Memphis (Patricia Flynn, Leader), and UCSD (SA Spector, Leader). These 4 CRSs have demonstrated the ability to enroll subjects into protocols involving numerous clinical trials networks including IMPAACT, ACTG, PHACS, ATN, INSIGHT, AERAS and DMID. These CRSs represent 4 of the 5 the highest accruing sites and the 4 highest CRSs in scientific contribution to the IMPAACT Network.
The Specific Aims of the HIV CURE CTU are: 1. Evaluate the pharmacokinetics, safety, and drug interactions of new and existing antiretroviral agents and formulations; 2. Evaluate novel approaches for tuberculosis prevention, treatment and diagnosis; 3. Develop and test biomedical/behavioral interventions to prevent HIV transmission between infected youth and their sexual partners and mother-to-child transmission (MTCT); 4. Evaluate the immunogenicity, safety and efficacy of vaccines of high priority in HIV-infected women, pregnant women, infants, children and youth; 5. Evaluate potential for HIV cure through therapeutic interventions aimed at prevention and clearance of HIV reservoirs; 6. Evaluate the pharmacokinetics, safety, and efficacy of new drugs and drug combinations to treat hepatitis B (HBV) and hepatitis C (HCV); and 7. Determine optimal and feasible methods for the prevention and management of complications of HIV infection and its treatment. The HIV Cure CTU will use its extensive capacity to recruit subjects into the IMPAACT, ACTG and HPTN Networks HIV-infected and at-risk populations that are historically underrepresented in clinical trials including minorities and people of color with an emphasis on women, pregnant women, youth, children and newborns which will broaden the applicability of clinical trials performed within the DAIDS networks.

Public Health Relevance

This CTU application combines 4 highly experienced and successful domestic CRSs to form the HIV Centers for Underrepresented Populations in Research (HIV CURE) CTU that will focus on recruitment to studies of the IMPAACT, ACTG and HPTN Networks HIV-infected and at-risk minority subjects with an emphasis on women, pregnant women, youth, children and newborns. Thus, this application is highly relevant to this RFA.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Roby, Gregg A,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California, San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Zhang, Gang; Luk, Brian T; Hamidy, Morcel et al. (2018) Induction of a Na+/K+-ATPase-dependent form of autophagy triggers preferential cell death of human immunodeficiency virus type-1-infected macrophages. Autophagy 14:1359-1375
Campbell, Grant R; Bruckman, Rachel S; Herns, Shayna D et al. (2018) Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem 293:5808-5820
Baker, Jason V; Sharma, Shweta; Achhra, Amit C et al. (2017) Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc 6:
Garg, Ankita; Trout, Rodney; Spector, Stephen A (2017) Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4. Sci Rep 7:44485
Bolton Moore, Carolyn; Capparelli, Edmund V; Samson, Pearl et al. (2017) CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS 31:1129-1136
Spector, Stephen A; Brummel, Sean S; Nievergelt, Caroline M et al. (2016) Genetically determined ancestry is more informative than self-reported race in HIV-infected and -exposed children. Medicine (Baltimore) 95:e4733
Singh, Kumud K; Qin, Min; Brummel, Sean S et al. (2016) Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS One 11:e0151364
Fowler, Mary G; Qin, Min; Fiscus, Susan A et al. (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 375:1726-1737
Brummel, Sean S; Singh, Kumud K; Maihofer, Adam X et al. (2016) Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity. J Acquir Immune Defic Syndr 71:544-50
Gupta, Amita; Montepiedra, Grace; Gupte, Akshay et al. (2016) Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants. PLoS One 11:e0148649

Showing the most recent 10 out of 26 publications